DMRA
Damora Therapeutics, Inc.
NASDAQ: DMRA · HEALTHCARE · BIOTECHNOLOGY
$25.36
-1.17% today
Updated 2026-05-01
Market cap
$1.46B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.98
Dividend yield
—
52W range
$2 – $38
Volume
0.3M
Damora Therapeutics, Inc. (DMRA) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
1 of 8
Last 8 quarters
Avg EPS surprise
+200.0%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+144.1%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+108.2%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+196.4%
2025-11-07
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-20 | $2.31 | +2236.9% | $19.20 | $23.05 | +20.1% |
| 2025-11-07 | $-2.36 | — | $5.82 | $17.25 | +196.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.11 | $2.31 | +2236.9% | — | — |
| 2025-09-30 | — | $-2.36 | — | — | — |
| 2025-06-30 | — | $-2.60 | — | — | — |
| 2025-03-31 | — | $-1.92 | — | — | — |
| 2024-12-31 | — | $-5.22 | — | — | — |
| 2024-09-30 | — | $-3.39 | — | — | — |
| 2024-06-30 | — | $-4.92 | — | — | — |
| 2024-03-31 | — | $-5.05 | — | — | — |
| 2023-12-31 | — | $-5.97 | — | — | — |
| 2023-09-30 | — | $-7.50 | — | — | — |
| 2023-06-30 | — | $-10.18 | — | — | — |
| 2023-03-31 | — | $-12.65 | — | — | — |
Frequently asked questions
Has Damora Therapeutics, Inc. beaten earnings estimates?
Damora Therapeutics, Inc. has beaten Wall Street EPS estimates in 1 of its last 8 quarterly reports, with an average EPS surprise of +200.0% over the last 1 quarters.
How does DMRA stock react to earnings?
DMRA stock has moved an average of +108.2% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.